Search results: (10000)
News Prophylaxis EHL products FVIII bring improvements in clinical and pharmacokinetic results
A freshly published real-world clinical practice study from Spain highlights the experience of switching patients with hemophilia A in a prophylaxis setting from standard half-life products to newer products with an extended elimination half-life.
News Benefits and Cost-Effectiveness of Superabsorbent Dressings in the Treatment of Venous Leg Ulcers
A recent cost-effectiveness analysis based on German data showed that using superabsorbent dressings instead of conventional dressings in the treatment of venous leg ulcers with moderate to high exudation increases the likelihood of healing, quality of life, and reduces direct healthcare costs. Similar results were found in another analysis from last year, this time using French data, comparing superabsorbent dressings with foam dressings, again in the treatment of venous leg ulcers.
News Postoperative Bleeding in Children with Hypofibrinogenemia Induced by Cardiopulmonary Bypass
Patients undergoing cardiac surgery with the use of cardiopulmonary bypass are at risk of up to a 40% reduction in plasma fibrinogen levels, with subsequent risk of perioperative bleeding. Children undergoing surgery for congenital heart defects are even more sensitive to the reduction in fibrinogen. What are the possible solutions, and is any one of them significantly better?
News If Suicides Were COVID-19... or Why We Still Overlook a Significant Cause of Premature Deaths?
More than a year since the start of the pandemic, the SARS-CoV-2 coronavirus has claimed 2.8 million lives globally, with 127 million recorded cases of COVID-19 (as of March 29, 2021). According to World Health Organization (WHO) data, there are 800,000 suicides annually, with suicide attempts being up to 20 times more frequent, totaling over 16 million. Given our current focus on physical health, are we overlooking the extent and importance of mental health issues in the population? This question has been raised by several experts from different countries in their submission to the February issue of The Journal of Clinical Psychiatry.
News Current NCCN Recommendations for Classification and Risk Symptoms in SLL/CLL
The new recommendations from the National Comprehensive Cancer Network (NCCN) regarding chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) from August 2022 also include a brief summary of the most common symptoms and methods for classifying the disease based on its extent at diagnosis or in case of progression.
News Register of Patients Treated with Growth Hormone (REPAR): Data Analysis as a Path to Further Optimization of Care
Treatment with recombinant growth hormone (rhGH) is available in the Czech Republic for all children meeting the indication criteria. A network of 10 centers covers the entire country, and all doctors authorized to prescribe growth hormone are united in the Pediatric Growth Hormone Working Group. The Czech national Register of Patients Treated with Growth Hormone (REPAR) has been collecting data on patients treated with rhGH since 2014. The aim of the presented work was to analyze selected data and present the basic demographics of patients included in this database during the first 5 years of its existence.
News Diosmin and its application in the treatment of venous insufficiency
A number of procedures, including pharmacotherapy, are used in the treatment of chronic venous insufficiency, in which diosmin, for example, is applied. The report by pharmacologist MUDr. Jiří Slíva, Ph.D., summarizes the mechanism of action and pharmacological properties of this substance.
News Is it possible to predict survival time based on laboratory or radiological findings in patients with IPF?
High-resolution computed tomography (HRCT) imaging of the lungs is a fundamental examination in diagnosing idiopathic pulmonary fibrosis (IPF). According to experts from the Mayo Clinic, it can also serve as a tool for more accurate prediction of survival time in IPF patients.
News Impact of Initial RAAS Inhibitor on Hospitalization Risk in HFrEF Patients
Inhibition of the renin-angiotensin-aldosterone system (RAAS) is considered a key step in the treatment of heart failure with reduced ejection fraction (HFrEF). The preferred medication currently is the angiotensin II receptor and neprilysin inhibitor (ARNI) sacubitril/valsartan, which has shown to improve the prognosis of patients with HFrEF. A recently published study compared the initiation of ARNI or angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) in patients with HFrEF who were not previously treated with a RAAS inhibitor in real-world practice.
News Impact of Candesartan on Achieving Remission in Patients with Active IgA Nephropathy
IgA nephropathy is the most common glomerulonephritis worldwide and in the Czech Republic. The effect of candesartan (an angiotensin receptor blocker) on the remission of active IgA nephropathy in patients treated with steroid pulses and tonsillectomy was investigated by the randomized study presented below.
News PHD 2022: In the treatment of multiple myeloma we have achieved significant progress, confirm real-world data
The treatment options for multiple myeloma (MM) have significantly advanced over the past 10 years, and patient outcomes have improved. However, the most accurate guide is needed to select the right treatment modality for each particular patient among the many available options. During the Prague Hematology Days (PHD) 2022, this topic was addressed by Prof. MUDr. Roman Hájek, CSc., from the Hemato-Oncology Clinic of the Faculty of Medicine at the University of Ostrava and FN Ostrava.
News Prognostic Significance of the Location of Colorectal Cancer Metastases
An Austrian study presented at the ESMO 2020 conference analyzed the relationship between the localization of colorectal cancer (CRC) metastases and patient survival, the time of metastasis detection, and RAS mutations.
News Evaluation of the m7-FLIPI score in patients with follicular lymphoma revealed a promising predictive biomarker for determining suitable chemotherapy
The authors of a study presented at the December congress of the American Society of Hematology (ASH) in Orlando introduced a new prognostic tool, m7-FLIPI, for determining the risk level of patients with follicular lymphoma (FL). They tested its utility using samples from the GALLIUM clinical trial and, during the analysis, discovered a promising biomarker that could help in selecting the primary chemotherapy for FL patients.
News Nirmatrelvir/ritonavir reduces the risk of hospitalization for COVID-19 even in the era of predominant omicron subvariants BA.4 and BA.5
One of the first studies to evaluate the efficacy of nirmatrelvir/ritonavir in non-hospitalized patients with COVID-19 infection during the period of predominant omicron variants including subvariants BA.4 and BA.5 has provided real-world data confirming the position of this antiviral in the first line of treatment for patients with mild to moderately severe SARS-CoV-2 infection and a high risk of severe disease.
News Progress on Lorlatinib – What's Next?
Lorlatinib is currently mainly used in the 2nd and later lines of treatment for non-small cell lung cancer (NSCLC) with ALK gene rearrangement. Clinical research is now focusing on the question of how to proceed with patients who experience disease progression during lorlatinib treatment in later lines of therapy. It seems that one of the options might actually be to do nothing – to continue with lorlatinib.
News Impact of Administering Omega-3 Fatty Acids on the Risk of Metabolic Syndrome in Patients with Schizophrenia
The aim of the Polish clinical study OFFER was to assess the possibility of influencing the risk of developing metabolic syndrome (MetS) and some of its individual components in patients with first-episode schizophrenia by supplementing with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
News Pharmacokinetics of Concentrates for the Treatment of von Willebrand’s Disease
Von Willebrand's disease (vWD) is characterized by a deficiency or reduced functional capacity of von Willebrand factor (vWF) and, in more severe cases, by a deficiency of coagulation factor VIII (FVIII). Treatment usually requires repeated infusions of vWF and FVIII concentrate, with available products having different factor ratios. Repeated infusions of concentrates can lead to different FVIII exposures when using different products. The pharmacokinetics of two products with varying vWF and FVIII ratios have been compared in experimental preclinical and clinical studies.
News Targeted DNA Sequencing Helps Find Targeted Therapy for Patients with NSCLC
Gene sequencing has become a key tool in deciding the treatment for patients with non-small cell lung cancer (NSCLC). At a university in Seoul, South Korea, a retrospective analysis of the benefits of targeted genetic testing in real clinical practice was conducted.
News Sequential administration of immunochemotherapy and venetoclax after failure of BCR inhibitor treatment – interactive video case study
The treatment of chronic lymphocytic leukemia (CLL) is evolving. What was impossible years ago is now becoming a reality. From chemotherapy, through immunochemotherapy, to the use of molecules targeting apoptotic pathways of tumor cells, the prognosis for patients has markedly improved. However, the wide therapeutic spectrum also brings its own specifics and complications, and the correct sequencing of treatment lines and their selection for each individual is necessary, considering the nature of CLL, overall condition, and comorbidities.
News Neuroprotective Efficacy and Safety of Vinpocetine in Patients with Acute Ischemic Stroke
A meta-analysis of 4 randomized placebo-controlled studies demonstrated the benefits of vinpocetine in patients with ischemic stroke (iCMP). Administering vinpocetine within 14 days of the onset of the stroke significantly reduced the level of disability and the proportion of those who died or were dependent on others after 1 and 3 months. The results showed benefits in several other parameters and indicated very good tolerability of this drug used to increase cerebral blood flow.
News Targeted Treatment of HER2-Positive Breast Tumors – Updates from ESMO 2020 Congress
The recent European Society for Medical Oncology (ESMO) Congress took place virtually. We bring you a brief summary of the presentations related to the treatment of HER2-positive breast tumors.
News Alpha-1-Antitrypsin Deficiency and Its Association with Atopy in Asthmatics
Literature mentions the coincidence of asthma and alpha-1-antitrypsin deficiency, which is caused by a mutation in the SERPINA1 gene. The aim of the study presented below was to determine whether the clinical symptoms of asthma differ between patients with and without this mutation.
News Fixed combination tiotropium/olodaterol in regular clinical practice: What do patients say?
A non-interventional international study assessed the therapeutic benefits of the fixed combination of tiotropium/olodaterol in the treatment of chronic obstructive pulmonary disease (COPD) in real-world practice through a questionnaire filled out by patients.
News Ocrelizumab in the treatment of multiple sclerosis in real-world practice – a systematic review of published studies
In controlled study programs, ocrelizumab has demonstrated beneficial effects on improving clinical parameters in patients with multiple sclerosis, such as the annual relapse rate or confirmed disability progression. However, to get a complete picture of its clinical benefit, real-world evidence in a broad patient population is also needed. A systematic review of real-world clinical practice studies with ocrelizumab, published in March 2023, demonstrates its benefits in patients with relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in terms of relapse frequency, disease activity on MRI, disability, absence of disease activity (NEDA), and quality of life.